Thrombosis Update最新文献

{"title":"Venous and arterial thromboembolism in out-patients with inflammatory bowel disease: a single center study","authors":"Antonella Tufano ,&nbsp;Anna Testa ,&nbsp;Marta Patturelli,&nbsp;Antonio Rispo,&nbsp;Vincenzo Fotticchia,&nbsp;Paola Rufolo,&nbsp;Federica Strano,&nbsp;Alessia Dalila Guarino,&nbsp;Antonietta Vitale,&nbsp;Olga Maria Nardone,&nbsp;Mario Ferrante,&nbsp;Rossella Caso,&nbsp;Fabiana Castiglione","doi":"10.1016/j.tru.2025.100212","DOIUrl":"10.1016/j.tru.2025.100212","url":null,"abstract":"<div><h3>Background</h3><div>Patients affected by inflammatory bowel diseases (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC), are at risk for thromboembolic events (TE). Patients with active/relapsing disease and those needing hospitalization and surgery show the highest risk. The thrombotic risk in out-patients with IBD is underestimated and poorly investigated.</div></div><div><h3>Objectives</h3><div>to evaluate the prevalence, clinical features and risk factors for thromboembolism in IBD out-patients.</div></div><div><h3>Methods</h3><div>From May 2021 to September 2023, consecutive IBD out-patients were evaluated for the presence of cardiovascular risk factors (smoking, arterial hypertension, diabetes mellitus, hypercholesterolemia) and history of TE. Patients with a history of TE (including coronary heart disease, stroke, transient ischemic attack- TIA-, deep vein thrombosis- DVT-, superficial vein thrombosis- SVT-, pulmonary embolism- PE-) were studied for thrombophilia.</div></div><div><h3>Results</h3><div>A total of 302 IBD outpatients were included in the study (154 CD; 148 UC; mean age: 41.23 ± 17.4 years). Twenty-three patients (23/302; 7.6 %) showed a thrombotic event: 14 UC patients (14/148; 9.4 %) and 9 CD patients (9/154; 5.8 %).</div><div>Among the 23 patients with TE, we observed 12 arterial thromboses (12/23; 52.2 %), including 7 cases of Myocardial Infarction (7/12; 58.3 %), 3 Ischemic Stroke (3/12; 25 %), 2 TIA (2/12; 16.7 %); and 11 episodes of venous thromboembolism (VTE) (11/23; 47.8 %), including 7 DVT (7/11; 63.6 %), 2 SVT (2/11; 18.2 %) and 2 PE (2/11; 18.2 %).</div><div>Among the 11 VTE patients 6 were affected by UC and 5 patients were affected by CD. 5 out of 12 arterial thrombosis patients were affected by CD and 7 patients by UC.</div><div>In the univariable analysis, several predictors showed a significant association with TE, including IBD activity (OR = 4.98, 95 % CI: 1.93–12.81), arterial hypertension (OR = 4.44, 95 % CI: 1.86–10.60), hypercholesterolemia (OR = 4.68, 95 % CI: 1.38–15.92), hematologic disease (OR = 6.55, 95 % CI: 1.13–37.85).</div><div>IBD activity (OR = 7.03, 95 % CI: 2.48–19.85), arterial hypertension (OR = 3.35, 95 % CI: 1.32–8.50), hypercholesterolemia (OR = 5.06, 95 % CI: 1.21–18.77), hematologic disease (OR = 12.58, 95 % CI: 1.87–69.87) and immune disease (OR = 19.39, 95 % CI: 1.29–289.60) were significantly correlated to TE events at multivariable analysis.</div></div><div><h3>Conclusions</h3><div>Out-patients with IBD presented a low but not negligible risk of TE, mainly correlated to the common cardiovascular risk factors described in the general population and to the presence of immunological and hematological disease. Clinicians should not underestimate thrombotic risk in these patients.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100212"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing end of life care in cancer Patients. Focus on antithrombotic treatment","authors":"Emmanouil S. Papadakis,&nbsp;Lucy A. Norris","doi":"10.1016/j.tru.2025.100213","DOIUrl":"10.1016/j.tru.2025.100213","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation","authors":"M. Jansson ,&nbsp;S. Själander ,&nbsp;V. Sjögren ,&nbsp;F. Björck ,&nbsp;H. Renlund ,&nbsp;A. Själander","doi":"10.1016/j.tru.2025.100210","DOIUrl":"10.1016/j.tru.2025.100210","url":null,"abstract":"<div><h3>Introduction</h3><div>Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are superior or non-inferior to warfarin in reducing the risk of stroke while at the same time having a similar or lower risk of bleeding. However, reduced doses are prescribed more often than expected from clinical practice and off-label underdosing is a frequent issue. The objective of this study was to compare effectiveness and safety between guideline and off-label dosing of DOACs.</div></div><div><h3>Materials and methods</h3><div>Auricula, a Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 47,355 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) after exclusion of 92,316 patients due to concomitant venous thromboembolism, previous mechanical heart valve (MHV) or previous data entry in Auricula. The median durations of follow up were 403, 419, 373 and 209 days in the on-label standard dose cohort, off-label reduced dose cohort, on-label reduced dose cohort and the off-label standard dose cohort respectively. Endpoints (stroke and major bleeding) and baseline characteristics were collected from hospital administrative registers using ICD-10 codes or the Swedish Stroke register. Cohorts were compared using weighted adjusted Cox regression after full optimal matching based on propensity scores.</div></div><div><h3>Results</h3><div>Off-label underdosing of DOACs (n = 6,187, 9.7 %) was associated with higher risk of major bleeding HR 1.16 (95 % CI 1.05–1.27), other bleeding HR 1.16 (1.04–1.30), myocardial infarction HR 1.47 (1.20–1.80), ischemic stroke HR 1.25 (1.04–1.50) and all-cause mortality HR 1.52 (1.37–1.69) compared to on-label standard dosing (n = 35,065, 55.2 %). Among off-label underdosed DOACs, dabigatran was associated with higher risk of all-cause stroke 1.86 (1.07–3.23), ischemic stroke HR 1.97 (1.10–3.52) and all-cause stroke and systemic embolism HR 1.92 (1.11–3.32) compared to apixaban. Rivaroxaban was associated with major bleeding HR 1.70 (1.41–2.03), gastrointestinal bleeding HR 1.92 (1.33–2.77), and other bleeding HR 1.97 (1.57–2.47) compared to apixaban. The study could not show any differences comparing off-label overdosing of DOACs and on-label reduced dosing, besides lower risk of all-cause mortality HR 0.69 (0.52–0.93) in the overdosed patients.</div></div><div><h3>Conclusions</h3><div>In this large observational registry-based NVAF cohort, underdosing of DOACs is associated with higher risk of ischemic and all-cause stroke but also major bleeding when compared to on-label dosing. Underlying DOAC therapy may need to be tailored to the specific patient when choosing off-label reduced dosing since underdosed rivaroxaban is associated with higher risk of bleeding complications, and underdosed dabigatran is associated with higher risk of stroke complications, when comparing both with apixaban.</div></d","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antithrombin supplementation to prevent venous thromboembolism: A case of hereditary antithrombin deficiency with increased antithrombin clearance during pregnancy and peripartum","authors":"Ayako Kaneda-Takeuchi ,&nbsp;Tomoaki Oda ,&nbsp;Mei Kitamoto ,&nbsp;Emiyu Fujiwara ,&nbsp;Kenta Kawai ,&nbsp;Megumi Narumi ,&nbsp;Yoshimasa Horikoshi ,&nbsp;Masako Matsumoto ,&nbsp;Yukiko Kohmura-Kobayashi ,&nbsp;Naomi Furuta-Isomura ,&nbsp;Toshiyuki Uchida ,&nbsp;Kazunao Suzuki ,&nbsp;Naohiro Kanayama ,&nbsp;Hiroaki Itoh ,&nbsp;Naoaki Tamura","doi":"10.1016/j.tru.2025.100211","DOIUrl":"10.1016/j.tru.2025.100211","url":null,"abstract":"<div><div>Hereditary antithrombin deficiency (HATD) is an autosomal dominant disorder that significantly increases the risk of venous thromboembolism (VTE) during pregnancy. Based on our experience with three previous cases and the Japanese clinical guidelines, we manage high-risk VTE in pregnant women with HATD using unfractionated heparin (UFH) and antithrombin (AT) supplementation from early pregnancy to the peripartum period. Herein, we report another case of HATD type 1 in pregnancy and evaluate changes in AT clearance. A 29-year-old woman had a history of pulmonary embolism (PE) at 14 years and a family history of HATD with AT activity of 47 % at baseline, which decreased to 31 % when she developed PE after an abortion. During her second pregnancy, she was treated with UFH and AT concentrate (ATC) with doses increasing from 50 to 100 IU/kg to achieve target AT activity levels of 50–60 % throughout pregnancy and 70 % during delivery. She delivered a healthy male infant at 39 weeks of gestation. She started to take warfarin on postpartum day 1, with an uneventful postpartum course. AT clearance, calculated using plasma AT antigen levels, showed notable increases in the first and late third trimesters, peaking around delivery and coinciding with elevated thrombin-antithrombin complex levels. These findings suggest increased AT consumption during these periods, which may contribute to unexpected decreases in AT activity. We propose close monitoring of AT activity and providing adequate ATC supplementation alongside anticoagulation throughout pregnancy, particularly during periods of elevated AT clearance, to minimize VTE risks in HATD patients.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100211"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study","authors":"Imene Deneche ,&nbsp;Camille Couffignal ,&nbsp;Nassima Si Mohammed ,&nbsp;Anette Arbjerg Højen ,&nbsp;Carme Font ,&nbsp;Stavros Konstantinides ,&nbsp;Marieke Kruip ,&nbsp;Luigi Maiorana ,&nbsp;Sebastian Szmit ,&nbsp;Denise Abbel ,&nbsp;Laurent Bertoletti ,&nbsp;Susanne Cannegieter ,&nbsp;Adrian Edwards ,&nbsp;Michelle Edwards ,&nbsp;Alessandra Gava ,&nbsp;Jacobijn Gussekloo ,&nbsp;Miriam J. Johnson ,&nbsp;Rashmi Kumar ,&nbsp;Johan Langendoen ,&nbsp;Kate Lifford ,&nbsp;Isabelle Mahé","doi":"10.1016/j.tru.2025.100209","DOIUrl":"10.1016/j.tru.2025.100209","url":null,"abstract":"<div><h3>Introduction</h3><div>To develop a European shared decision support tool (SDST), a Delphi process will be used to reach consensus about aspects relating to the continuation or deprescribing of antithrombotic therapy (ATT) in cancer patients at the end of life. As part of the SERENITY project, this study corresponds to work package (WP) 4.</div></div><div><h3>Methods</h3><div>Findings from SERENITY WPs 1–3 (realist review, flash mob research, epidemiological and qualitative studies) informed the Delphi study. The WP4 steering committee had two objectives. (1) to build a representative expert panel comprising physicians, pharmacists, nurses and psychologists from eight European countries; and (2) to advise on the content of the Delphi form, divided into four sections: context, content, SDST design and trial outcomes. The form was reviewed by the SERENITY patient and public involvement group to ensure that it met patients’ needs. The Delphi study will take place in three rounds held at 6-week intervals, involving experts from eight countries. Consensus will be reached on items with at least 70 % agreement. The steering committee will review and validate the results across the different rounds.</div></div><div><h3>Results</h3><div>Through this Delphi study, the following aspects will be defined: characterisation of candidate patients for discussion about ATT deprescribing; healthcare team roles in ATT decision-making; specific information and communication requirements for patients when making deprescribing decisions; SDST content priorities; and optimal outcomes for the planned clinical trial.</div></div><div><h3>Conclusion</h3><div>This study will feed directly into the development and evaluation of the SDST, aimed at reducing complications and improving quality-of-life in end-of-life cancer patients receiving ATT.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of oral aspirin in prevention of embolic events in infective endocarditis: A systematic review and meta analysis","authors":"Jonathan Victor Salazar-Ore ,&nbsp;Angie Carolina Alonso-Ramírez ,&nbsp;Gabriela Vanessa Flores-Monar ,&nbsp;Emily Patricia Solarte-Zabaleta ,&nbsp;Miguel Ángel Castaneda-Diaz ,&nbsp;Ada Lizandra Motino-Villanueva ,&nbsp;Anuj Manish-Kakkad ,&nbsp;Camila Sanchez-Cruz ,&nbsp;Ernesto Calderón-Martínez","doi":"10.1016/j.tru.2025.100208","DOIUrl":"10.1016/j.tru.2025.100208","url":null,"abstract":"<div><h3>Introduction</h3><div>Infective endocarditis (IE) involves inflammation of the heart's inner lining and valves, leading to complications like embolic events. The role of aspirin in preventing these events is controversial, with concerns about bleeding risk, limiting its use. This meta-analysis evaluates the effectiveness of oral aspirin in preventing embolic events and its adverse outcomes in IE patients.</div></div><div><h3>Methods</h3><div>A systematic search was conducted on July 20, 2024, across PubMed/MEDLINE, Cochrane, Scopus, Web of Science, EMBASE, and CINAHL for studies comparing aspirin to placebo or no treatment. The protocol was registered in PROSPERO (CRD42024573274).</div></div><div><h3>Results</h3><div>Five studies involving 1174 participants were included, with three eligible for meta-analysis due to data limitations. Findings on embolic event incidence were inconsistent: one randomized clinical trial (RCT) excluding prior aspirin therapy (OR 1.62, [0.68–3.86], p = 0.29) and a reanalysis examining long-term use (OR 0.80, [0.36–1.78], p = 0.582) found no significant reduction, while another study reported a possible reduction (OR 0.65, [0.43–0.98], p = 0.04). Bleeding rates trended higher in aspirin groups across two studies, though not statistically significant. Mortality data also varied; one study found higher mortality in aspirin users, while another associated chronic antiplatelet therapy with lower mortality, particularly with early initiation after admission.</div></div><div><h3>Conclusion</h3><div>Aspirin may reduce embolic events in IE, but evidence remains inconclusive due to mixed findings. Aspirin showed a non-significant increase in bleeding risk and mortality, so routine use for embolic prevention in IE is not recommended, highlighting the need for further research to clarify its potential role.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144088817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National and regional incidence patterns of venous thromboembolism in Finland during 1998–2021 with corresponding mortality trends in 1998–2019","authors":"Lasse Myllylahti ,&nbsp;Jari Haukka ,&nbsp;Eero Hirvensalo ,&nbsp;Riitta Lassila","doi":"10.1016/j.tru.2025.100207","DOIUrl":"10.1016/j.tru.2025.100207","url":null,"abstract":"<div><h3>Objectives</h3><div>Previous research suggest that venous thromboembolism (VTE) -related mortality have been declining over the recent decades, despite the increasing trend of pulmonary embolism (PE) incidence. There is evidence of some regional differences in VTE incidence. We wanted to evaluate the national and regional 21st century VTE incidence in Finland, as well as respective national VTE mortality trends.</div></div><div><h3>Patients and methods</h3><div>In this nationwide registry study, anonymous participants were patients with VTE diagnoses (I26 or I80) during hospital visits or VTE-related documentation of primary cause of death. To assess incidence, we recorded VTE-related hospital visits from the HILMO registry of the Finnish Institute for Health and Welfare. To assess mortality, we recorded deaths with a VTE diagnosis as a primary cause of death from the registries of Statistics Finland. Additionally, we acquired the data about pulmonary CT angiographies from STUK, which is the radiation and nuclear safety authority in Finland.</div></div><div><h3>Results</h3><div>At the national level, the PE incidence doubled during the study period, while the incidence rates of deep vein thrombosis remained stable. Some regional variances in VTE incidence were encountered. The usage of radiological examinations to diagnose PE have become more frequent during the study period. The mortality for VTE peaked in 2004, following the clear declining trend during the follow-up period.</div></div><div><h3>Conclusion</h3><div>Despite the remarkable increase in PE incidence, the mortality rates have been constantly declining from 2004. These results are valuable for the future epidemiological research of VTE.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100207"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound assisted, catheter-directed thrombolysis for acute intermediate-high risk pulmonary embolism: Focus on safety for oncological patients","authors":"Claudia Colombo ,&nbsp;Lorenzo Tua ,&nbsp;Nicolò Capsoni ,&nbsp;Francesco Musca ,&nbsp;Ilaria Emanuela Bossi ,&nbsp;Filippo Russo ,&nbsp;Mario Iannaccone ,&nbsp;Andrea Discalzi ,&nbsp;Luciana D'Angelo ,&nbsp;Fabrizio Oliva ,&nbsp;Marco Solcia ,&nbsp;Alice Sacco","doi":"10.1016/j.tru.2025.100206","DOIUrl":"10.1016/j.tru.2025.100206","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100206"},"PeriodicalIF":0.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel method for pulmonary embolism prognosis: Right to left ventricular volume ratio (RLVR) on pulmonary angiography (CTPA)","authors":"Aykut Yucal,&nbsp;Mustafa Burak Sayhan","doi":"10.1016/j.tru.2025.100203","DOIUrl":"10.1016/j.tru.2025.100203","url":null,"abstract":"<div><h3>Introduction</h3><div>Right ventricular dysfunction is the main cause of mortality in patients with acute massive pulmonary embolism (PE) and early diagnosis is extremely important. This study aimed to investigate whether the right/left ventricular volume ratio (RLVR) calculated using pulmonary angiography (CTPA) is a valuable tool for PE prognosis.</div></div><div><h3>Method</h3><div>Clinical, echocardiographic and pulmonary angiography data of cases diagnosed with pulmonary embolism in the emergency department between January 2021 and December 2023 were retrospectively evaluated. Patients were stratified according to the presence of massive PE, one month mortality and pulmonary embolism severity index (PESI) score. Clinical, laboratory and radiographic parameters were compared to search for prognostic factors.</div></div><div><h3>Results</h3><div>Of the 210 patients, the mean age was 67 ± 15 years, 46 % were male, and 42 % had massive PE. The right/left ventricular volume ratio was significantly higher in patients with massive PE, in those who died within one month after admission; and in patients with PESI Class III. When the cut-off value of right/left ventricular volume ratio was accepted as &gt;1.7, its predictive value for acute PE mortality was higher than other CTPA and echocardioraphy measurements (AUC = 0.706).</div></div><div><h3>Conclusion</h3><div>An increased right/left ventricular volume ratio on CTPA, a valuable tool for diagnosing right ventricular dysfunction, is associated with a worse prognosis in subjects with pulmonary thromboembolism.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100203"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimorbidity and VTE","authors":"Lucy A. Norris (Editors in Chief),&nbsp;Emmanouil S. Papadakis (Editors in Chief)","doi":"10.1016/j.tru.2025.100204","DOIUrl":"10.1016/j.tru.2025.100204","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"18 ","pages":"Article 100204"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}